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ABSTRACT 
 The Regulator of G protein Signaling 4 (RGS4) has previously been 
shown to prevent prolonged vasoconstriction by binding to the Gq heterodimer. 
However, the known anti-inflammatory role of RGS4 has not been applied to 
reperfusion injury in the context of G protein signaling. The aims of this study is 
to elucidate the expression pattern of RGS4 in renal reperfusion injury to 
determine if cell signaling initiated by Angiotensin II, a known ligand of Gαq 
coupled-receptors, is modulated by RGS4. LacZ reporter animals were used to 
characterize RGS4 expression during reperfusion. Human smooth muscle cells 
co-cultured with human endothelial cells demonstrated that AngII induces 
apoptosis in the absence of RGS4 and initiates RANTES expression in smooth 
 iv 
 
muscle cells. SMMHC-Cre rgs4fl/fl confirmed the role of vascular smooth muscle 
cells to inhibit macrophage localization during reperfusion injury. RGS4 
expression in vascular smooth muscle cells therefore inhibits AngII-mediated 
oxidative stress, leukocyte recruitment by the same cell type, and endothelial 
damage prior to tubular epithelial injury. 
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INTRODUCTION 
 
 
G protein-coupled receptors (GPCRs) are seven-transmembrane domain 
receptors that activate signal transduction pathways leading to a cellular 
response. GPCRs enable transmission of signals throughout the cell or between 
cells of varying distances in the body. Interestingly, the signaling components 
inside the cell were first described in molecular detail before the intricate details 
regarding the mechanism of the receptor was established. Numerous Nobel 
laureates have been recognized for their work with the signaling components, 
dating back to the Nobel Prize in Physiology or Medicine in 1971 awarded to Dr. 
Earl W. Sutherland, Jr. for discovering the second messenger cyclic AMP and 
adenylyl cyclase. A few decades later, the Nobel Prize in Physiology or Medicine 
was awarded to Dr. Martin Rodbell and Alfred G. Gilman for their discovery of 
cyclic AMP-dependent protein kinase and heterotrimeric G-proteins in 1994. 
Finally, understanding the function and importance of GPCRs is highlighted by 
the 2012 Nobel Prize in Chemistry awarded to Dr. Brian K. Kobilka and Robert J. 
Lefkowitz for their studies in the molecular mechanism of this modular system. 
Evidently, this process is widely accepted as significantly important to the 
advancement of science and medicine through the numerous Nobel Prizes 
awarded in this field of research. As a result of the work done by Kobilka and 
Lefkowitz, GPCRs are now the target of approximately 40% of modern medicinal 
drugs (1).  
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GPCRs contain α, β, and γ subunits, where the α-subunit can dissociate 
from the others once GPCRs exchange a guanosine diphosphate (GDP) for a 
guanosine triphosphate (GTP). This disassociation continues to activate 
intracellular signaling pathways. In the context of the kidney, the activation of 
GPCRs in the lining of the microvasculature plays a key role in the early 
development of ischemic reperfusion injury (IRI) (2-5). Reperfusion injury occurs 
after a period of ischemia when tissues are deprived of oxygen and nutrients. 
The absence of these factors creates an environment in which a restoration of 
circulation causes inflammation and oxidative damage, as opposed to re-
establishing normal function. The inflammatory response is attributed to returning 
white blood cells releasing interleukins and other inflammatory factors, in addition 
to free radicals in response to the tissue damage. Additionally, the white blood 
cells may further produce ischemia by binding to the endothelium of small 
capillaries and obstructing them. The reintroduction of oxygen also causes 
oxidative stress and damages cellular proteins in addition to the plasma 
membrane and the DNA. The damage to the cell membrane can proceed to 
produce more free radicals, reacting with redox signaling and turning on 
apoptosis. Clinically, acute tubular necrosis develops within 24 hours of ischemia 
as a culmination of these several processes, beginning with endothelial injury 
and followed by pathologic vasospasm, leukocyte infiltration, and tubular 
epithelial cell injury. 
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Ischemic reperfusion injury is especially prominent and a significant in 
kidney transplantation, where blood flow must be ceased during the procedure. 
As a result of kidney transplantation, IRI is the major cause of acute renal failure 
and may increase the likelihood of chronic kidney disease. The early 
inflammatory response of ischemic reperfusion injury can be initiated by ligands 
such as angiotensin II and endothelin-1, which are cognate binding partners of 
the Gq alpha subunit in GPCRs (5, 11). In the context of ischemic kidney injury, a 
decreased flow rate in the kidney causes a perturbation in blood flow at the 
juxtaglomerular apparatus in the macula densa. This is detected by 
baroreceptors and in response, the juxtaglomerular apparatus stimulates the 
release of renin. Circulating renin can proceed to hydrolyze angiotensinogen, a 
452 amino acid long protein produced by the liver, into the peptide angiotensin I. 
Angiotensin I is then further cleaved by angiotensin-converting enzyme (ACE) 
into the strong vasoactive octapeptide angiotensin II. To the interest of this study, 
a decreased flow rate in the kidney also stimulates leukocyte adhesion receptors 
on endothelial cells to bind circulating macrophages (13, 14). Macrophages 
contain a high concentration of ACE, which facilitates the local generation of the 
Angiotensin II (15).  
Angiotensin II can activate local cytokine signaling in the vascular smooth 
muscle cell, provoke activation of the coagulation cascade on the surface of the 
endothelial cell, induce leukocyte adhesion in arterioles, and induce endothelial 
cell senescence (17-20). Once circulating macrophages transmigrate to the site 
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of injury, high levels of angiotensin converting enzyme in these cells can then 
locally concentrate Angiotensin II activity and perpetuate the inflammatory 
response. Upon inflammation, the production of the chemokine ligand 5 (CCL5), 
also known as RANTES (regulated on activation, normal T cell expressed and 
secreted), functions as a chemotactic cytokine attracting T cells, eosinophils, 
basophils, and leukocytes to the inflammatory sites. 
Regulators of G protein signaling (RGS) proteins are multi-functional 
proteins that have been identified in activating GTPases for heterotrimeric G-
protein alpha-subunits. As GTPase-activating proteins (GAP), they are capable 
of inhibiting GPCR signal transductions by preventing the exchange of GDP for 
GTP. RGS proteins are known to function in a variety of cell types including 
vascular smooth muscle cells, cardiomyocytes, and cortical neurons. They have 
also been recognized to contain anti-inflammatory effects in the vascular system 
as it applies to atherosclerosis and diabetic cardiomyopathy (6-8). However, the 
anti-inflammatory role of RGS proteins has not been applied to reperfusion injury 
in the context of G protein signaling. 
In the renal vasculature, RGS proteins have been identified as a key 
component of the vasomotor activity of vascular smooth muscle cells (9, 10). 
RGS4 in particular is a subtype of the RGS proteins and has been primarily 
associated with schizophrenia, but it has also been recognized to have a role in 
the kidney vasculature. RGS4 appear to modulate vascular tone during ischemic 
kidney injury and become upregulated in vascular smooth muscle cells 
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susceptible to atherosclerosis (10). The Gq alpha subunit in Gαq-containing 
receptors (GαqR) is a well-known binding partner of RGS4 (16). By binding to the 
Gq heterodimer, it inhibits endothelin function and prevents prolonged 
vasoconstriction. This contributes to a decrease in angiotensin-dependent 
superoxide production and prevents fatty acid uptake and oxidation (6, 11). In 
lung epithelial cells, RGS4 diminishes cell growth whereas kidney epithelial 
expression of RGS4 has not been reported (12). 
The capacity of RGS4 in vascular smooth muscle cells to inhibit local G 
protein-coupled signaling in the context of reperfusion injury remains unproved. 
In this study, the role of RGS4 expression in the renal microvasculature to 
mitigate inflammatory-mediated injury is to be investigated. More specifically, this 
study aims to elucidate the expression pattern of RGS4 in renal reperfusion injury 
and determine if cell signaling initiated by Angiotensin II, a known ligand of Gαq 
coupled-receptors, is modulated by RGS4. The hypothesis is that RGS4 is 
expressed in vascular smooth muscle cells to inhibit angiotensin II-mediated 
oxidative stress in addition to leukocyte recruitment and endothelial damage prior 
to tubular epithelial injury. Angiotensin II would induce apoptosis in the absence 
of RGS4 and initiate RANTES expression in smooth muscle cells. Thus, during 
ischemic reperfusion injury, vascular smooth muscle cells would inhibit 
macrophage localization. 
To accomplish these goals, LacZ reporter animals are used to 
characterize RGS4 expression during reperfusion, in addition to transgenic eGFP 
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reporter animals in demonstrating resistance to kidney reperfusion injury and to 
confirm results from LacZ reporter animals. A form of dynamic magnetic 
resonance imaging, fast imaging with steady-state procession (FISP), is adapted 
to measure and evaluate small changes in renal blood flow. Additionally, primary 
human arterial vascular smooth muscle cells (VSMC) and human arterial 
endothelial cells (EC) are used to study the effects of RGS4 on inflammatory cell 
signaling cascades induced by Angiotensin II. The response of VSMC to 
Angiotensin II will be measured by a RANTES immunoassay as levels of 
RANTES secreted by VSMC will be increased upon exposure to Angiotensin II. 
Lastly, a smooth-muscle cell specific RGS4 null mouse will be created with a 
tamoxifen-inducible smooth muscle cell myosin heavy chain (SMHHC) promoter 
to drive expression of Cre recombinase. The animal will then be crossed to a 
floxed animal rgs4fl/fl to create a conditional null mouse SMHHC-Cre rgs4fl/fl. This 
animal model will confirm that RGS4 expressed in myosin-containing cells 
functionally buffers the inflammatory signal generated during reperfusion injury. 
As a result of this study, the role of RGS4 in kidney reperfusion injury and 
repair will be elucidated and potentially serve as an essential target in future 
treatment or prevention of acute kidney injury during renal transplantation.  
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METHODS 
 
Murine warm renal ischemia/reperfusion surgery: 
All research involving the use of mice were performed in strict accordance 
with protocols approved by the Animal Studies Committee of Harvard Medical 
School. Adult male C57/B6 congenic controls and RGS4 transgenic (R4Tg), or 
SMMHC-Cre and SMMHC-Cre rgs4fl/fl mice were anesthetized with a mixture of 
xylazine (16 mg/ kg) and ketamine (80 mg/kg). Core temperature was maintained 
between 36.5 – 37.5 C. Simultaneous bilateral renal pedicle clamping was 
employed using a 60G microaneurysm clip for each renal artery. First, a left flank 
incision was made and the kidney was exposed. A pedicle clamp was placed on 
the left main renal artery under direct visualization using a Zeiss OPMI 6 Surgical 
Microscope (12.5x optic, f=175mm). After 25 minutes of ischemia each clamp 
was released and removed. The incisions were closed and the animal was 
allowed to recover. 
Ultra-mild ischemia reperfusion injury: 
Animals were anesthetized, maintained between 36.5 – 37.5˚ C and under 
direct visualization hilar fascia was dissected to separate the ureter from the 
renal blood supply. A 60G microaneurysm clip was applied to the left renal artery 
for 10 minutes and released. The incisions were closed and the animal was 
allowed to recover. Imaging analysis proceeded 18 hours after clamp release. 
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Dynamic Magnetic Resonance Imaging: 
All dynamic MR images were generated in the Beth Israel Deaconess 
Medical Center Small Animal Imaging Facility. High-relaxivity gadolinium chelate 
(Multihance, gadobenate dimeglumine, 529mg/mL, Bracco Diagnostics) was 
administered in a standard weight-based protocol throughout the study. Mice 
were sedated using 1.5% inhaled isoflurane throughout the imaging procedures. 
Contrast agent was injected in mice through a 28g flexible venous jugular 
catheter (SAI Inc.) placed prior to the initiation of the scanning protocol. Mice 
were secured in a prone position and fitted in a bird cage-designed body coil. 
The 9.4-T MRI scanner (Bruker Biospin GmbH) employs an actively shielded 
assembly a 20-cm warm bore diameter. Data acquisition was processed using 
TopSpin 3.1 software (Bruker Biospin GmbH). Anatomic imaging confirmed 
animal position and was immediately followed by the dynamic imaging protocol. 
Imaging protocol parameters included echo time, 1085ms; repetition time 
2170ms; excitation pulse angle, 60; flip angle, 30; FOV 2x2 cm; matrix size 
128x96; slice thickness, 1.5mm. When the procedure ended the mice were 
returned to a clean containment cage to recover. 
Bayesian Analysis Software is open software available through the 
Washington University in St. Louis Biomedical Magnetic Resonance Laboratory. 
It was used to process all dynamic MR imaging. It employs Random walk Monte 
Carlo methods to sample the distributed intensity vs. time plots defining the local 
rate change of gadolinium transit through the kidney and therefore local blood 
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flow. Blood flow calculations relied on assumptions of gadolinium contrast transit 
through the vascular space as described below. 
Renal blood flow is a practical calculation to understand the hemodynamic 
state of the kidney before, during, and after an ischemic event. It is made of 
component parts which contribute to the final calculation of RBF including arterial 
contrast in-flow rate (α), arterial contrast out-flow rate (β). Each variable was 
measured in arbitrary units and therefore a matched control was compulsory to 
interpret results. 
Local arterial input function (CA(t)) was based on the temporal 
concentration change of contrast agent inflow ((t-t0)
α) and outflow (exp [- β(t-t0)]) 
summarized as the gamma variate (GV): 
GV(t) = ((t-t0)
α) exp [- β(t-t0)]) 
Distributed over a time interval and accompanied by a normalization constant the 
arterial input function can be represented in terms of the gamma variate (GV):  
CA(t) = aGV(t,t0)+c 
This multi-dimensional integral was constructed to account for the 
properties of contrast in-flow, out-flow, and recirculation, within single voxels of 
space. Posterior probabilities were derived from conditional probabilities by 
applying Bayesian evidential probability theory (21). Parameters were 
constructed based on the known properties of gadolinium contrast in the kidney 
(22-25). The parameters of each conditional prior probability were fit to a 
Gaussian distribution accounting for the properties of a bolused solution in a 
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vascular compartment (26). 50 Markov chain Monte Carlo simulations were 
repeated 50 times fitting signal intensity to integral kernels over a time period 
required for 100 image acquisitions. Each signal intensity kernel was correlated 
with kernels acquired prior and afterward in time sequence to best identify a 
logical equilibrium distribution. This approach prevented illogical scenarios that 
chronologically transpose α and β or disobey known dispersion properties of 
gadolinium contrast in a vascular space. 
Measure of contrast transit time from renal artery to renal vein in shunted 
renal blood flow was used as an internal control to characterize gadolinium 
contrast through the vasculature compared to urinary excretion. We then 
captured data from cortical and medullary regions of interest to determine 
intravascular contrast transit during the first 50s post-bolus interval avoid the 
component of urinary filtration. 
If distinct change in signal intensity could not be seen between the cortex 
and medulla prior to contrast injection the corticomedullary junction was defined 
as pixel distance from outermost cortex to hilum x 0.5. 
In vivo imaging of monocrystalline nanoparticles: 
MION 47 (monocrystalline iron oxide nanoparticle) (Center for Molecular 
Imaging Research, Massachusetts General Hospital, Harvard Medical School) 
was injected in mice through a 28g flexible venous jugular catheter (SAI Inc.) 
immediately before renal ischemic injury. An MR imaging protocol (Rapid 
Acquisition with Relaxation Enhancement with variable repetition time 
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[RAREVTR]) was performed 18 hours after injury and incorporated the following 
parameters: echo time 12.6, 37.7, 62.9, 88.1, 113.2, 138.4, 163.5, 188.7ms; FOV 
2x2cm; matrix size, 256 x 192 pixels; slice thickness, 1mm; interlaced images, 3. 
Protein analysis: 
Cytosolic protein lysates from dissected kidney or cell lysate were 
prepared for immunoblot analysis using Triton X lysis buffer including pepstatin 
(1μg/mL), leupeptin (5μg/mL), and MG-132 (10μM) as preservatives. PVDF 
membranes were extensively washed in TBS/T then incubated with horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody (Amersham, 
a GE Healthcare Company, Pittsburgh, PA, USA). Bands were visualized by use 
of the ECL system (Amersham). Scanned blot densitometry was performed with 
Image J (v1.24) software. 
Doppler-based blood flow monitoring: 
Blood flow was measured by Doppler flowmetry as we described earlier 
(27). The apparatus measures red blood cell transit time between two optical 
fibers interfaced with a photodetector to transform the Doppler shift in light 
frequency to an electrical signal. The procedure requires a flank incision, 
dissection of fascia and exposure of the kidney. Surface doppler probe was 
applied to the medial aspect of the kidney at the midpole. Red cell velocity was 
measured every minute for one hour. Renal artery blood velocity was measured 
using an Advanced Laser Flowmeter 21 (ALF21, ADVANCE Co., Tokyo, Japan). 
Mice were anesthetized with a mixture of xylazine (16 mg/kg) and ketamine 
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(0.080 mg/g). A sham procedure was performed exposing the right kidney but 
maintaining its blood supply. Medullary blood flow was measured using the same 
flowmetry device. The kidney was exposed, renal capsule removed at the cortical 
apex. A small insertion point was made with jeweler’s forceps to insert the 
Doppler probe. 
Tissue preparation histology and analyses: 
For renal histology 8 micron thick paraffin kidney sections were routinely 
stained with hematoxylin and eosin. X-gal staining involved sectioning tissue 
blocks frozen in Optimal Cutting Tissue compound (Torrance, CA). Tubular injury 
was assessed in at least 10 non-overlapping fields using a 20x objective. 
Vascular smooth muscle cell-endothelial cell co-culture was prepared for 
immunohistochemistry with 8% paraformaldehyde (PFA) fixation. Cells were then 
blocked with 5% bovine serum albumin (BSA) in PBS for one hour. Monoclonal 
anti-RGS4 antibody (1:400; Abcam) and anti-cleaved caspase 3 (1:200) primary 
antibody were diluted in 5% BSA and applied to cells for 6 hours at 4°C. After 
washing the primary antibody, cells were incubated in α-hamster Cy3 (1:100; 
Abcam) and α-rabbit FITC (1:200) diluted in 5% BSA for one hour on ice. Cells 
were washed once more and then mounted with Vectashield and 4’,6-diamidino-
2-phenylindole (DAPI) (Vector Laboratories). The procedure was also done 
separately with PECAM (1:100; SantaCruz) and SMA (1:75) as primary antibody 
and α-Goat Cy3 (1:200; Jackson ImmunoResearch) with reapplied SMA (1:75) 
as secondary antibody. 
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To calculate a tubular injury score kidney sections were processed after 
24hrs of reperfusion and were evaluated for tubule flattening, necrosis, 
apoptosis, or presence of casts as a percentage of total number of tubular 
epithelial cells per high power field. 
RGS4 signal intensity was quantified in histologic sections using ImageJ 
software to outline non-overlapping pixel areas surrounding the peritubular 
capillaries in cross-section and excluding the apical membrane and urinary space 
of the tubular epithelial cells. Signal intensity was normalized to baseline values 
in wild type control mice undergoing sham surgeries. Calponin-1 + cells in the 
peritubular capillary (PTC) space were identified if >75% of the capillary lumen 
stained positive for Cy3 fluorescence in the presence a DAPI+ cell embedded in 
the wall of the PTC. 
Prussian Blue Staining: 
Slides were first deparaffinized and rehydrated. Equal parts of 20% hydrochloric 
acid and 10% potassium ferrocyanide were mixed immediately before use. Slides 
were then immersed in this solution for 20 minutes, followed by three rinses with 
distilled water. Nuclear fast red was used as a counterstain and slides were 
rinsed twice in distilled water. Slides were then dehydrated with 95% ethanol and 
twice with 100% ethanol, followed by two changes of xylene for three minutes 
each. Permount was used as a mounting medium to coverslip the slides. 
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Dihydroethidium staining: 
10μM dihydroethidium (DHE) (Life technologies, Carlsbad, CA) was 
applied to live cells using the same technique as Owusu-Ansah and colleagues 
(28) with the following modifications. Vascular smooth muscle cells were grown 
to confluence and treated with 1x10-7M AngII for 12 hours. Media was changed 
and plated cells were exposed to fresh media with 3.2mM DHE for 10 minutes. 
Each 12 well plate was analyzed during a 5 minute span using a Nikon Eclipse Ti 
live-cell imaging microscope under conditions of 21% O2 and 6% CO2. Each 
successive well was analyzed in the same sequence beginning with vehicle 
plasmid control (DHE+vehicle), vehicle with AngII (1x10-8M) (DHE+AngII), and 
pCMV-RGS4 plasmid with AngII (1x10-8M) (DHE+AngII+pCMV/RGS4) 
respectively. Signal intensity (SI) was calculated per pixel area (PA) of individual 
nuclei using ImageJ software as a percentage of intensity exceeding the vehicle 
control condition. 
LDH Assay: 
Abcam LDH-Cytotoxicity Assay Kit II was used. Cells were collected and 
wash once with culture medium. A 96-well plate was used and 100μl of culture 
medium without cells in triplicates served as background control. For low control, 
100μl of cells in culture medium were used in triplicate wells. For high control, 
10μl of Cell Lysis Solution was added to the 100μl of cells in triplicates and 
mixed. Lastly, for test sample, 100μl of cells in triplicates were mixed with 
angiotensin II to determine cytotoxicity. The absorbance of all controls and 
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samples were measured with a plate reader at 650nm. This measures the level 
of lactate dehydrogenase through the detection of NADH, which is produced by 
the release of LDH oxidizing lactate. NADH then reacts with WST reagent to 
generate a yellow color. Percent cytotoxicity was then determined by the 
difference between test sample and low control divided by the difference 
between high control and low control, multiplied by 100. Cytotoxicity (%) = (Test 
Sample - Low Control)/(High Control - Low Control) x 100 CCL5/RANTES 
Immunoassay. All reagents were brought to room temperature before use. 
Samples were collected from cell culture supernatants. Calibrator Diluent RD6-11 
was diluted with distilled water to 20% (v/v) to form Calibrator Diluent RD6-11 
(5x) working solution. 
Standards were prepared using 1:1 serial dilutions diluted in Calibrator 
Diluent RD6-11 (5x), starting from 2000pg/mL of RANTES Standard to 
31.2pg/mL. 100μL of standards, control, and sample were added into wells on a 
microplate containing 100μL of Assay Diluent RD1W. Microplate was then 
covered with adhesive strip and incubated for 2 hours at room temperature. 
Following incubation, wells were aspirated and washed twice with 400μL of Wash 
Buffer, inverting plate and blotting against clean paper towels after last wash. 
200μL of RANTES Conjugate was then added and incubated for an hour at room 
temperature with a new adhesive strip covering microplate. Wells were then 
aspirated and washed as before. Color Reagents A and B were then mixed in 
equal volumes to form a working Substrate Solution. 200μL of Substrate Solution 
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were added into each well and incubated for 20 minutes at room temperature, 
protected from light. Optical density was measured at 450nm, with wavelength 
correction of 570nm. 
Magnetic microbead-based Cytokine Immunoassay: 
Adult vascular smooth muscle cells (Sciencell) were grown to 95% 
confluence and stimulated with Angiotensin II in a series of dose titration 
conditions. Cells were washed and lysed with NP40 lysis buffer containing 
pepstatin (1μg/mL), leupeptin (5μg/mL), and MG-132 (10μM). Multi-analyte 
microsphere-based fluorometric assay was performed at EMD-Millipore (St. 
Charles, MO) using Luminex technology (Luminex Inc.) under the manufacturer’s 
specifications. Confirmation of Luminex results was performed using set AngII 
dosing (1x10-8M) with progressive time-points. Samples were processed using a 
Human CCL5/RANTES ELISA kit (R&D Systems Inc.) and results were 
processed with a plate reader detecting chemiluminescence at 450nm 
wavelength. 
Human Vascular Smooth Muscle Cell-Vascular Endothelial Cell Co-culture: 
Co culture development followed techniques previously described (29, 
30). Briefly Human vascular endothelial cells (EC) and human vascular smooth 
muscle cells (VSMC) from a donor without medical co-morbidities (ScienCell 
Research Laboratories) were used between P4 to P7. Under sterile technique 
ECs were applied to partitioned wells 2.2cm in diameter and grown to 
approximately 90% confluence in endothelial cell medium (ECM) (ScienCell). 
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Separately VSMCs were cultured to 95% confluency. 1X103 VSMCs were then 
applied at an angle with a micropipettor to the wall of the partitioned well to 
insure proximity to ECs. After six hours, the partition was removed. Media was 
changed every 12 hours. Experiments were performed within 48 hours of co-
culture generation. Co-culture was treated with 500μM H2O2. 
MRI calculations: 
Single pixel regions of interest were averaged in the cortex of the superior, 
mid and inferior kidney pole, and in the medulla of the superior, mid-, and inferior 
kidney pole. Blood flow was calculated as previously described (31) using a local 
arterial input function rather than a global arterial input function (32). pcDNA-
RGS4 plasmid was given as a gracious gift from Dr. Yong Tae Kwon, University 
of Pittsburgh. Construct details have been previously described (33). This 
construct was transiently transfected into human vascular smooth muscle cells 
using lipofectamine 2000 (Invitrogen). 
SMMHC x RGS4 flox design: 
The gene targeting vector included a neomycin resistance cassette to 
select for screened embryonic stem cells incorporating the target sequence into 
the genome by recombination. Embryonic stem cells of interest were then 
injected into an E3.5 blastocyst and transferred into a foster mother at the 
Washington University in St. Louis Mouse Genetics Core. Heterozygous offspring 
were then bred and crossed with other heterozygotes until both floxed RGS4 
alleles were consistently expressed through germline transmission. Floxed RGS4 
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genotyping included the following primer sequences, GCA GCA CTT CCT ACG 
GAC TCT C (sense) and CTG GAC CAC, ATT CCT TCA TTC A (antisense). 
SMMHC Cre mice were a gift, first generated by Dr. Stefan Offermanns and 
maintained by Dr. Kenneth J. Blumer. SMMHC Cre animals were genotyped with 
the following primer sequences TGA CCC CAT CTC TTC ACT CC (sense), AAC 
TCC ACG ACC ACC TCA TC (antisense). Genotyping was performed as a 
service of Transnetyx, Inc. 
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RESULTS 
 
RGS4 expression in the microvasculature of the kidney prior to and subsequent 
to ischemic injury 
RGS4 has been identified in medium-caliber arteries of the kidney with a 
β-galactosidase (βgal) gene knock-in reporter system (10). RGS4 expression in 
smaller renal vascular structures such as arterioles and capillaries is unknown. 
Accurate localization has been limited by the lack of highly specific antibodies to 
the protein. As a result, multiple animal reporter systems are used including 
knock-in or BAC transgenic designs. Truncated expression patterns are a known 
limitation of reporter systems that use β-galactosidase reporter techniques (34). 
In this study, a system that expresses β-galactosidase at the rgs4 gene locus 
(RGS4- βgal) was compared to a RGS4 reporter system that inserts the coding 
sequence for enhanced green fluorescent protein (eGFP) in a bacterial artificial 
chromosome construct (BAC) with stable integration of the construct in the 
animal’s genome (35). By comparing both reporter systems RGS4 expression 
patterns were confirmed that are less likely due to the idiosyncratic nature of the 
individual reporter types. Further, the RGS4-eGFP mouse (RGS4-Tg) was used 
as a relative overexpressor to contrast the previous description of the rgs4 null 
mouse (10, 36). 
At baseline RGS4 promoter-driven βgal is expressed at low levels in 
regions of the kidney consistent with small vascular structures (Figure 1A-C). In 
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RGS4-Tg animals RGS4 co-localizes with smooth muscle myosin heavy chain 
positive (MHC+) cells in the kidney consistent with arteriolar structures (Figure 
1D). RGS4 expression in vascular smooth muscle cells appears distinct from 
endothelial cells (Figure 1D). Shortly after ischemic injury, βgal expression 
increases in the corticomedullary junction (Figure 2A). MHC+ cells contain 
increased levels of RGS4 protein shortly after injury (Figure 2B). RGS4 also is 
present in the urinary space after injury but is not present in the cytosol or 
nucleus of intact tubular epithelial cells (Figure 2B). 
It was hypothesized that the increased RGS4 protein expression at 
baseline in RGS4-Tg kidneys (Figure 2C) would be protective to the kidney in the 
setting of ischemia-reperfusion injury in small vessels expressing RGS4 and 
contrast the phenotype of rgs4 null mice (2). Following moderate IRI serum 
creatinine improved in comparison to congenic controls (Figure 2C) and 
corresponded with a reduced amount of tubular injury. Whether this protective 
effect is mediated solely by vasorelaxation or also by anti-inflammatory activity 
was unclear due to the known multimodal properties of RGS4 in the vasculature. 
RGS4 prevents endothelial activation prior to tubular injury 
To isolate the influence of vascular smooth muscle cells on adjacent 
endothelial cells prior to tubular epithelial cell injury we devised a model to 
evaluate renal hemodynamics following ultra-mild IRI (UMIRI) (see methods). 
Subsequent to UMIRI endothelin-1 serum levels and calponin-1 expression 
normalized consistent with a level of vasomotor tone equivalent to non-injured 
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animals less than 18 hours after injury (37, 38). Endothelial activation was 
evident with a decrease in thrombomodulin levels. Tubular injury scores indicated 
no presence of ATN after ischemia (data not shown). 
Fast imaging with steady-state precession (FISP) is a form of dynamic 
magnetic resonance imaging capable of measuring small alterations in blood 
flow. Using FISP MR imaging parameters we adapted this technique to measure 
renal blood flow (Figure 3). Local arterial input function avoided the need for 
deconvolution of global arterial function (see Methods). Rate change of contrast 
inflow (α) correlated closely with rate change of contrast outflow (β) whereas 
renal blood flow measures did not correlate directly with either α or β. Small 
regions of interest were analyzed with a computational algorithm using Bayesian 
analytic techniques (31) which demonstrated a difference in blood flow most 
apparent at the corticomedullary transition zone. We observed a redistribution of 
flow after injury in congenic controls while RGS4-Tg animals maintained 
perfusion parameters in the corticomedullary junction approaching those 
observed in shams (Figure 3). We evaluated a separate group of animals for 
blood flow by Doppler flowmetry as previously described (10) but could not detect 
differences from baseline (data not shown). Immediately following imaging 
kidneys were processed to assess for tubular injury. 
Corresponding with in vivo imaging results endothelial cells in peritubular 
capillaries contained less thrombomodulin representing a procoagulant state on 
the surface of the endothelial cells. Animals with a relative increase in RGS4 
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expression at baseline (RGS4-Tg) maintained thrombomodulin levels in 
peritubular capillaries (Figure 3C) while tubular epithelial cell injury was not 
detected by tubular injury scoring or by in situ staining for KIM-1, a sensitive 
biomarker of epithelial injury. The low levels of thrombomodulin correlated with 
an increase in VCAM expression in the same congenic controls undergoing 
UMIRI (Figure 3D). RGS4-Tg also displayed less ED1+ cells in the kidney 
compared to congenic controls. On the premise that RGS4 is expressed in 
vascular smooth muscle cells the above results infer a local relay of information 
between the vascular smooth muscle cell and the endothelial cell prior to tubular 
epithelial cell injury. 
Angiotensin II-mediated endothelial cell injury is inhibited by RGS4 expression in 
vascular smooth muscle cells 
Angiotensin II (AngII) serum concentrations are elevated early in the 
reperfusion phase of kidney IRI and may contribute to reperfusion injury though 
activation of its cognate Gαq-containing GPCR (39). Primary human arterial 
vascular smooth muscle cells were cultured to study the effect of RGS4, a Gαq 
binding partner, on inflammatory cell signaling cascades induced by AngII. This 
work contrasts our previous studies that demonstrated RGS4 is a vasomodulator 
of endothelin, also a cognate ligand to the GαqPCR found in kidney VSMC (10). 
First it was found that RGS4 is expressed in VSMC in vitro. Upon exposure to 
AngII, superoxide free radical production was evident in VSMC but decreased in 
VSMCs constitutively expressing RGS4 (pCMV-RGS4) (Figure 4A). Similarly, 
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VSMCs transfected with pCMV-RGS4 and exposed to AngII displayed a 
reduction in SMAD-2 phosphorylation compared to VSMCs transfected with 
RGS4 siRNA (Figure 4B). 
Specificity of this inflammatory signaling pathway through the GαqPCR 
was supported by Gαq-siRNA transfection of VSMC. With suppressed synthesis 
of the αq subunit VSMC were relatively protected from angiotensin-II induced 
oxidative injury. Treatment with hydrogen peroxide resulted in equivalent cellular 
damage for both RGS4-expressing and αq-depleted conditions (Figure 4C). This 
result in addition to the salutary effect of Gαq-depletion suggests a GPCR-
specific pathway mediating AngII-induced inflammatory signaling in VSMC. 
To identify if VSMC respond to AngII by recruiting immune cells to the sight of 
injury we screened for 30 common signaling cytokines (Figure 4D). Levels of 
RANTES, a monocyte chemoattractant secreted by vascular smooth muscle 
cells, increased in response to Angiotensin II exposure at relatively low 
concentrations and in a dose-dependent fashion (Figure 4D). 
We inferred that recruitment of circulating immune cells by endothelial 
cells may be inhibited by RGS4 expressed in adjacent VSMC as demonstrated 
by preserved thrombomodulin content in RGS4-Tg undergoing UMIRI. This lead 
us to investigate the effect of VSMC on adjacent endothelial cells. Reviewing the 
histologic distribution of RGS4 in RGS4-eGFP reporter mice there was no 
evidence that endothelial cells express RGS4 (Figure 2D-4). Therefore we 
created a co-culture environment consisting of human arterial vascular smooth 
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muscle cells (Figure 5A) that express RGS4 and human arterial endothelial cells 
(EC) that do not (Figure 5B). A confluent co-culture environment was generated 
containing VSMC and EC with maintained phenotypes at the VSMC-EC junction. 
Co-culture was then transfected with RGS4 siRNA and subsequently exposed to 
Angiotensin II. After 12 hours co-culture conditions were analyzed for production 
of cleaved caspase-3 (CC3). RGS4 siRNA transfected conditions demonstrated 
increased levels of CC3 in endothelial cells compared to adjacent VSMC 
expressing RGS4 (Figure 5C). 
RGS4 expressed in myosin+ cells in the kidney compartment protects against 
leukocyte migration in reperfusion injury 
To confirm that RGS4 expressed in myosin-containing cells functionally 
buffers the inflammatory signal generated during reperfusion injury a smooth-
muscle cell specific RGS4 null mouse was created using a tamoxifen-inducible 
smooth muscle cell myosin heavy chain (SMHHC) promoter to drive expression 
of Cre recombinase (40). This animal was crossed to a floxed animal rgs4fl/fl 
(RGS4-fl) to create a conditional null mouse SMHHC-Cre rgs4fl/fl (Figure 6). 
Under moderate IRI conditions SMMHC-RGS4-fl were very sensitive to renal 
injury. We demonstrated in above experiments that enhanced RGS4 expression 
reduces the density of a macrophage surface adhesion molecule, VCAM-1, in the 
kidney after ischemic insult and that in vitro the macrophage-localizing cytokine 
RANTES is expressed by vascular smooth muscle cells in response to to AngII 
treatment. We therefore used monocrystalline iron oxide nanoparticles to localize 
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phagocytic cells, primarily macrophages (41), in the kidney. In vivo MR imaging 
identified nanoparticle density in SMHHC-Cre rgs4fl/fl kidneys beyond that of 
congenic controls undergoing IRI. This correlated with an increased density of 
Prussian blue staining in the same region of the inner cortex and outer medulla 
where T2 signal was most intense (Figure 6D). 
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DISCUSSION 
 
Based on the above studies, a previously unknown anti-inflammatory 
function was identified in the kidney which resides in cells with contractile 
capacity. In particular, expression of RGS4 in smooth muscle cell-containing 
arterioles and peritubular capillaries decreases inflammatory signals that are 
transmitted through angiotensin II receptor activation in the formative stages of 
reperfusion injury. 
Potential therapeutic targets for the treatment of renal reperfusion injury 
are emerging (42, 43). In this context the endothelial-smooth muscle cell junction 
is central to a complete understanding of the initiation of reperfusion injury. We 
acknowledge that the endothelial cell response generates a change in the 
contractile state of the adjacent VSMC, but in contrast we identified a route of 
inflammatory signaling that is primarily transmitted from the VSMC to the 
endothelial cell by activation of the GαqR and can be dampened by binding 
RGS4 to the Gαq subunit. Based on our results we propose RGS4 is the primary 
RGS subtype which binds to the α-subunit in receptors of the vascular smooth 
muscle cells in the kidney. 
The disease process of reperfusion injury has been viewed as disparate 
from that of ischemia which centers on aberrant vasoconstriction in vascular 
smooth muscle cells and leads to a cessation of metabolic processes in oxygen-
depleted cells. Although GPCR ligands are implicated in pathologic 
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vasoconstriction in the setting of ischemic injury, the role of the same GPCR’s in 
subsequent reperfusion injury has been widely unexplored. Our report suggests 
that local AngII generation contributes to renal reperfusion injury in the 
microvasculature of the peritubular capillaries by inducing oxidative injury. The 
extracellular surface of the endothelial monolayer becomes densely populated 
with cell adhesion molecules such as VCAM allowing macrophages to aggregate 
in the kidney. Macrophages that contain a high concentration of angiotensin 
converting enzyme can then diapedesis to the interstitial space of the kidney, 
magnifying the local concentration of AngII and perpetuate an inflammatory 
response. 
To balance the effect of AngII, RGS4 expressed in VSMC of the kidney 
changes quantitatively before and after ischemic injury as we demonstrated in β-
gal expression studies. Prior to insult RGS4 is distributed throughout the afferent 
and efferent arterioles of the outer cortex and less intensely in the inner cortex 
and outer medulla. Upregulation occurs soon after ischemic injury and most 
apparently in the region of the corticomedullary junction. Co-staining with myosin 
heavy chain antibody therefore identifies RGS4 expression in a cell type with 
organized contractile capacity; this in comparison to scar-forming cells such as 
smooth muscle actin + fibroblasts. RGS4 expression pattern in RGS4-eGFP 
reporter animals also co-localize with MHC inferring that β-gal expression is not 
driven by the knock-in design, but instead by the endogenous expression pattern 
of RGS4. Historically, polyclonal RGS4 antibodies have been complicated by 
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non-specific antigen binding giving impetus to the number of in vivo RGS4 
reporter systems. Now available monoclonal RGS4 antibodies have assisted in 
the re-validation of the animal reporter systems, which we show to overlap in 
their expression patterns. 
The RGS4 BAC transgenic model, consistent with other BAC transgenic 
designs, expresses enhanced levels of RGS4 at baseline. This model system 
offers an in vivo setting to study the effect of elevated RGS4 levels prior to insult. 
We identified RGS4 to be upregulated by kidney IRI however this effect was 
difficult to synchronize prior to injury. Further, in models of atherosclerosis, 
chronic angiotensin II administration can downregulate RGS4 expression (6). 
Therefore to more predictably enhance RGS4 function investigations are 
underway to identify small molecules that do not interact with the Gαq binding 
cleft and can therefore prolong GTPase activity non-competitively (44, 45). 
Aware that RGS4 expression is concentrated in the vascular smooth muscle cells 
containing the myosin heavy chain 11 a conditional knockout model was studied 
to decipher the signaling role of RGS4 during reperfusion. To avoid the 
vasoconstrictive component of reperfusion injury and at the same time identify 
the influence of VSMC-expressed RGS4 on endothelial cells we employed an 
ultra-mild ischemic injury technique. 18 hours post-ischemia there was no 
evidence of actin-myosin engagement in the inner cortex where renal blood flow, 
by FISP imaging, was shown to be altered. A high density of VCAM was 
identified at the same time point where, macrophages, with a propensity to 
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uptake iron oxide nanoparticles, also localized. The signaling sequence 
paralleled our isolated cell experiments that identified RANTES, a macrophage 
chemoattractant, to be secreted by VSMC. 
In summary, early inhibition of GPCR signaling modulates renal blood flow 
and prevents vasoconstriction at a time when distal tissue is oxygen depleted. 
During reperfusion RGS4 resists the generation of oxygen free radicals through 
the inhibition of Angiotensin II signaling thereby preventing the influx of 
macrophages triggered by endothelial cell damage. 
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FIGURES 
Figure 1 
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Figure 1. RGS4 expression in the kidney of β-gal knock-in and eGFP 
transgenic reporter systems. (A) Composite images were analyzed for 
baseline RGS4-driven β-gal expression. (B) The outer cortex expresses β-gal in 
the afferent and efferent arterioles of glomeruli (g) (scale bar 25μ). (C) β-gal 
expression (black) in the inner cortex (scale bar 125μ, 25μ respectively) (top row) 
is visualized with bright field microscopy overlayed with immunofluorescent 
staining of anti-α smooth muscle actin antibody (SMA) (green) and anti-smooth 
muscle myosin heavy chain antibody (MHC) (red) (scale bar 25μ) (bottom row). 
(D) RGS4 expression in the eGFP transgenic reporter system is present in 
arterioles and capillaries (white arrow) adjacent to tubules (t) (top row). Mid-sized 
vessels express RGS4 in SMMHC+ cells in the medial wall adjacent to PECAM+ 
cells in the intimal lining (scale bar, 50μ) (bottom row).  
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Figure 2 
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Figure 2. RGS4 expression in renal tissue before and after ischemic injury 
and the effect of RGS4 overexpression. (A) RGS4-LacZ reporter mice express 
SMMHC (red) consistent with typical histologic location of peritubular capillaries 
adjacent to epithelial tubular cells (green epifluorescence) in animals undergoing 
sham ischemic kidney injury (scale bar 125μ) (top row). The animals express β-
galactosidase (black, bright field) after mild injury most accentuated 4 hours after 
ischemia (bottom row) (*, p<0.05, ANOVA pair-wise comparison of 4 hour 
timepoint to all groups, n=4-5 animals per group). (B) A similar expression 
pattern is identified in non-transgenic animals analyzed with anti-RGS4 
monoclonal antibody (red). Structures consistent with arterioles and peritubular 
capillaries contain both SMMHC and RGS4 before (top row) and 4 hours after 
(bottom row) mild renal injury (*, p<0.05, ANOVA pair-wise comparison of 4 hour 
timepoint to all groups, n=4-5 animals per group). (C) RGS4-Tg animal 
expresses 4.6±0.8 fold (n=5 per group) more RGS4 protein at baseline compared 
to congenic controls as determined by immunoblot technique. Cortical kidney 
tissue from congenic controls and RGS4-Tg animals, respectively, underwent 
hematoxylin and eosin staining to evaluate cellular structures for damage using 
the tubular injury scoring method. 48 hours after injury sCr in control animals 
increased to 1.3±0.1 vs RGS4-Tg 0.4±0.2; 72 hours, 0.38±0.1 vs 0.88±0.2 (n=4 
for each group) (*, **, and ***, p<0.05 by ANOVA pairwise comparison between 
animal groups at each respective timepoint) (scale bar, 25μ).  
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Figure 3. Dynamic MRI of the kidney in ultra-mild ischemia reperfusion 
conditions. (A) Kidney distribution of gadolinium contrast 18 hours after sham 
(first window) or ischemic injury (second window). The inverse of the gadolinium-
dependent T1 signal intensity per unit time was plotted (red) and overlayed to the 
result of Markov chain Monte Carlo simulations (blue) excluding residual data 
(green) fitting integral intensity kernels to their temporal association with each 
other over the initial post-bolus 50 second interval. (B) Blood flow was 
interrogated with individual pixel areas (yellow) in the cortex (c), corticomedullary 
junction (cm) and medulla (m) and is presented as a ratio of regional perfusion 
compared to matched congenic shams (*, p<0.05 by ANOVA single-tail pairwise 
comparison of CM perfusion; **, p<0.05, student’s T-test, medullary perfusion, 
Tg+I vs Cg+I). (C) Peritubular capillaries stained for thrombomudulin expression 
in RGS4-Tg at baseline. (D) Kidney tissue stained for VCAM expression in non-
transgenic (top row) vs RGS4-Tg (bottom row) 18 hours after UMIRI. 
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Figure 4. RGS4 affects Angiotensin II-induced oxidative stress in VSMC.  
(A) Conditions include VSMC with pCMV vector alone (DHE+veh), pCMV + AngII 
(DHE+AngII), and pCMV/RGS4+AngII (DHE+AngII+pCMV/RGS4). DHE signal 
intensity (SI) is normalized to pixel area (PA) per condition (*, p<0.05, by ANOVA 
single-tail pairwise comparison; n=4-5 per group). (B) After AngII stimulation 
VSMC protein lysates were separated by SDS-PAGE followed by immunoblotting 
with primary monoclonal antibodies directed against RGS4, phosphorylated-
SMAD2 (pSMAD2), phosphorylated-ERK1/2 (pERK1/2), and α-actin as loading 
control. (*,p<0.05, RGS4+AngII vs. all groups; Ɨ, vehicle + AngII (veh+) vs. RGS4 
siRNA+AngII (si+); ƗƗ, pCMV/RGS4+AngII (R4+) vs. all groups; Δ, si+ vs. veh+; Δ 
Δ, R4+ vs vehicle alone (veh-); §, R4+ vs siR+; all comparisons by ANOVA 
calculation; n=4-5 per group. (C) Plasmid vector transfected VSMC treated with 
AngII (pCMV) resulted in 25.9±8.3% LDH release into the supernatant compared 
to VSMC transfected pCMV-RGS4 (10.4±4.4%) (p<0.05, *, pCMV-RGS4 vs 
pCMV, **, αq-Si vs PCMV; ANOVA pair-wise comparison; n=5-7 per group). (D) 
Intracellular VSMC content was analyzed by a Luminex-based assay containing 
microbeads specific to: IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α, MIP-1β, M-CSF, 
MIP-2, MIG, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), LIF, IL-13, LIX, 
G-CSF, Eotaxin, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-3, RANTES, VEGF, 
TNFα . (Left inset) Intracellular VSMC content was measured for RANTES levels 
dependent on concentration. (Right inset) Supernatant was measured for 
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RANTES content dependent on time of exposure (*,p<0.05, 0.01μM vs all 
groups; **, p<0.05, 6hr vs ctrl and 3hr by ANOVA).  
Figure 5 
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Figure 5. Characterization of vascular smooth muscle cell – endothelial cell 
co-culture. (A) Vascular smooth muscle cells express smooth muscle actin 
(green) and endothelial cells express PECAM (red); single cell expression in far 
right inset. (B) RGS4 expression in VSCM-EC co-culture. (C) Co-culture 
containing scrambled siRNA in VSMC without AngII treatment (top row), with 
RGS4 siRNA in VSMC with AngII treatment (middle row), and scrambled siRNA 
in VSMC with AngII (bottom row) (*,** p<0.05, by one-way ANOVA pairwise 
comparison to scrambled siRNA without AngII).  
 
 
 
 
 40 
 
          F
ig
u
re
 6
 
 41 
 
Figure 6. Vascular smooth muscle cell-specific deletion of RGS4 and in 
vivo response to ischemic kidney injury. (A) RGS4 floxed design and RGS4 
transcript and RGS4 protein expression after Cre-recombinase induction by 
tamoxifen. (B) Representative regions of interest (medulla tracing shown, yellow) 
after ischemia and MION-47 injection in SMMHC-Cre (WT), RGS4-Tg (Tg), and 
SMMHC-Cre rgs4 null mice (Fl) respectively with corresponding representative 
T2 signal decay curves. (C) Calculated T2 signal of kidney (T2k) compared 
calculated T2 signal of adjacent psoas muscle (T2m) (*, **, p<0.05, pairwise 
ANOVA, n =4 animals per group). (D) Prussian blue staining of corticomedullary 
junction in congenic control, RGS4-Tg, and SMMHC-RGS4KO, after ischemia 
and MION-47 injection *, **, p<0.05, pairwise ANOVA, n =4 animals per group.  
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